We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Tampilkan postingan dengan label prostate. Tampilkan semua postingan
Tampilkan postingan dengan label prostate. Tampilkan semua postingan

Kamis, 13 Oktober 2011

Prostate testing's dark side: Men who were harmed

AppId is over the quota
AppId is over the quota
Terry Dyroff's PSA blood test led to a prostate biopsy that didn't find cancer but gave him a life-threatening infection.

In the emergency room several days later, "I didn't sit, I just laid on the floor, I felt so bad," said Dyroff, 65, a retired professor from Silver Spring, Md. "I honestly thought I might be dying."

Donald Weaver was a healthy 74-year-old Kansas farmer until doctors went looking for prostate cancer. A PSA test led to a biopsy and surgery, then a heart attack, organ failure and a coma. His grief-stricken wife took him off life support.

"He died of unnecessary preventive medicine," said his nephew, Dr. Jay Siwek, vice chairman of family medicine at Georgetown University. "Blood tests can kill you."

Since Friday, when a task force of independent scientists said routine PSA testing does more harm than good, urologists who make a living treating prostate cancer have rushed to defend the test, as have patients who believe it saved their lives.

Less visible are men who have been harmed by testing, as Dyroff and Weaver were. The harm is not so much from the test itself but from everything it triggers — biopsies that usually are false alarms, and treatments that leave many men incontinent or impotent for cancers that in most cases were not a threat.

Once a PSA test suggests a problem, many men can't live with the worry that they might have cancer. And once cancer is found, most men feel they have to treat it, usually at the urging of their urologist.

"There are many men who have had serious consequences from treatment. Those stories don't get told and they are not uncommon," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, which thinks the task force reached "an appropriate conclusion" about the PSA test.

"I'm not going to criticize men who believe that their lives have been saved by this test," because that's what doctors have told them, Lichtenfeld said. "If you're sitting there and you wet your pants three times a day, you've got to believe it's worth it, that it saved your life."

Many men who agree to a PSA test do not understand what it is. Some common misconceptions:

— It shows cancer. In fact, PSA is just a measure of inflammation, and it can be elevated for many reasons besides cancer: normal enlargement of the prostate with age, an infection, even recent sex, a strenuous bike ride or horseback riding.

— It's been proven to save lives. Only two large, well-done studies have looked at this, the task force says. The American study found annual screening did not lower the chances of dying of prostate cancer. However, cancer fear is so great, and belief in the value of screening so ingrained, that half the men assigned to the group not offered PSA tests got one anyway. That made comparisons to the group given annual screening difficult. For that reason, some doctors don't believe the study's conclusion.

The other study, conducted in Europe, found a small benefit for certain age groups screened every two to seven years — not annually. However, one Swedish center had such rosy results that scientists think it may have biased the whole study. If that center is excluded, no benefit from the PSA test is seen.

— The task force's stance goes against past advice. Routine PSA testing has been supported by some advocacy groups and by urologists, the doctors who do the tests and treatments. But it has not been pushed by major scientific groups, the American Cancer Society or the government.

— It finds cancer early so you're more likely to survive. About 90 percent of prostate cancers found through screening are early-stage. Most will grow so slowly they will never threaten a man's life, but there's no good way to tell which ones will. Research suggests that tumors causing symptoms are more likely to warrant treatment than those that are not. Also, finding aggressive prostate tumors early may not affect how lethal they prove to be; the PSA test may just let men learn of them sooner than they otherwise would.

The task force said that in the European study, the rate of overdiagnosis from PSA screening — finding cancers that do not need to be treated — was estimated to be as high as 50 percent. Based on that study, 1,410 men would have to be screened, and 48 patients would have to be treated, just to save one life from prostate cancer.

Yet the public perception is that if PSA testing finds a cancer early, it must be good.

"Most people tend to think 'if it may help, I'm all for it.' But we don't know if it will help," said Siwek, the Georgetown doctor whose uncle died.

Once a PSA test suggests a problem, "it's hard to stop the conveyor belt or the cascade effect" that leads to more testing and treatment, said Siwek, who also is editor of the journal American Family Physician. "The inclination is, 'I've got to do something about it.'"

Dyroff, the retired professor, agreed to a biopsy after a blip in his PSA. Days later, he ran a high fever, felt weak and faint, and spent three days in the hospital fighting a bloodstream infection. A week later he relapsed and required a combination of intravenous antibiotics to finally recover.

A recent Johns Hopkins University study found surprisingly high rates of hospitalization after prostate biopsies and a 12-fold greater risk of death in those who develop infections.

Tony Masraff, a Houston restaurant owner, reluctantly agreed to a biopsy and then was diagnosed with prostate cancer in 1999. His urologist pushed surgery and balked when Masraff asked about other options such as radiation. After some research, Masraff decided just to monitor his tumor, and has seen his PSA rise very slowly over more than a decade.

Now 74, he hasn't had treatment "and I never will," he said. "I'm not concerned because I don't want the debilitative effects — I don't want to wear a diaper, and I like women."

"There's a huge number of people that are being operated on that don't need treatment," said Masraff, who formed a foundation for research into less invasive options.

The need to find a better screening tool is the real message from the task force, said Dr. Christopher Logothetis, prostate cancer research chief at the University of Texas M.D. Anderson Cancer Center in Houston. It may even be that there are better ways to use the PSA — employing it as a baseline test and tracking its rise over time — that might prove better than annual testing.

"If the debate gets reduced to 'there's a right and a wrong,' we will lose what we are being told here, which is to search for the path forward," he said.

The cancer society's Lichtenfeld agreed. "Maybe it's time to listen to evidence instead of hope," he wrote in his blog.

___

Online:

Task force recommendations: http://www.uspreventiveservicestaskforce.org/tfcomment.htm

Task force evidence report: http://bit.ly/ovhKUW

PSA decision guide: http://bit.ly/cXq1QE

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Associated Press

Technology



News

Vitamin E May Increase Risk of Prostate Cancer

AppId is over the quota
AppId is over the quota

Adding to the evidence that regularly taking dietary supplements may do more harm than good, researchers at the Cleveland Clinic have found that men taking vitamin E are not protected from prostate cancer, and may even be at higher risk for disease, compared with men not using the supplements.

The new study is only the latest blow to E, a popular supplement that has been touted as a powerful way to prevent everything from prostate and breast cancer to heart disease, vision loss and Alzheimer's. In recent years, however, in-depth studies have broken vitamin E's healthy spell, finding that people who take it are no better off than people who don't.

Still, based on animal studies and early population studies, scientists had believe that vitamin E supplementation could be a smart and inexpensive way to prevent prostate tumors, given that the vitamin's antioxidant effects may combat potentially damaging changes to the DNA in prostate cells.

"This finding was surprising, because all the evidence previously suggested that vitamin E may be protective against prostate cancer," says the Cleveland Clinic's Dr. Eric Klein, lead author of the new study published in the Journal of the American Medical Association.

MORE: Multivitamins, Dietary Supplements Linked to Death in Older Women

The current study is a follow-up to one of the first rigorous studies of the effects of vitamin E and selenium on prostate cancer risk, published by Klein and colleagues in 2008. That study, in which men were randomly assigned to take either supplement, or both together, or a placebo, Klein and his team found no difference in cancer risk among any of the groups, suggesting that vitamin E offered no protective anticancer benefit. Based on those results, the study was stopped. Additional analysis revealed that vitamin E may even boost risk of developing tumors.

To further understand what was going on, Klein continued the study with the majority of participants, who had stopped taking supplements but had agreed to continue providing information on their prostate cancer status for an additional 18 months.

In that time, Klein and his team found that even after the men had stopped taking vitamin E, their risk of prostate cancer remained higher than that of men who had originally been assigned a placebo. "The effect seemed to continue even after the supplements stopped," he says, suggesting that vitamins have powerful effects on body systems that may have lasting consequences. "People have to get out of the idea that taking vitamins is innocuous, and that their effects stop when they stop taking them."

Klein doesn't know exactly how vitamin E may increase the risk of prostate, but is hoping that his biobank of tissue samples from participants in the trial, which contains their starting levels of vitamin E and selenium, might provide some clues. By accounting for these baseline levels of the vitamin, he or others hope to determine whether it's vitamin E itself, or whether it's the dose of the vitamin, that may be contributing to prostate cancer. For example, people who are deficient in vitamin E may be able to take supplements safely and may even benefit from some anticancer effect, while those who are already getting enough of the vitamin may, by taking extra doses, trigger some as-yet unknown mechanism that prompts prostate cancer cells to grow abnormally.

MORE: Eating Fruits and Veggies May Outwit Bad Heart Genes

So, it's still possible that vitamin E supplements may help prevent some disease. So far, the most promising results are with Alzheimer's patients. In some studies, people with early signs of dementia show slower rates of cognitive decline if they take vitamin E than if they don't. But even here, the evidence isn't strong enough for doctors to recommend that those on the road to Alzheimer's take E to ward off their disease.

Overall, it seems, the growing consensus is that unless you need supplements to treat a specific deficiency, nutrients and vitamins are best obtained through a healthy diet. And that goes for E as well, says Klein, since it won't help you avoid cancer. "There doesn't seem to be much benefit to taking vitamin E if you are otherwise healthy," says Klein.

Alice Park is a writer at TIME. Find her on Twitter at @aliceparkny. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



News



Debt Financing

Vitamin E pills linked with prostate cancer risk

AppId is over the quota
AppId is over the quota
In this Monday, Oct. 10, 2011 photo, Joe Latina, 71, is shown on his porch at his home in Ashtabula, Ohio. Latina participated in a study involving vitamin E pills. Vitamin E pills are linked with an increased risk for prostate cancer, according to follow-up data from a study aiming to see if the supplements could prevent the disease but halted when there were signs of possible harm. Men who had been randomly assigned to take vitamin E were 17 percent more likely to get prostate cancer than those given dummy pills, the follow-up report found. (AP Photo/Tony Dejak) In this Monday, Oct. 10, 2011 photo, Joe Latina, 71, is shown on his porch at his home in Ashtabula, Ohio. Latina participated in a study involving vitamin E pills. Vitamin E pills are linked with an increased risk for prostate cancer, according to follow-up data from a study aiming to see if the supplements could prevent the disease but halted when there were signs of possible harm. Men who had been randomly assigned to take vitamin E were 17 percent more likely to get prostate cancer than those given dummy pills, the follow-up report found. (AP Photo/Tony Dejak) In this Monday, Oct. 10, 2011 photo, Joe Latina, right, 71, walks with his wife, Rita, along the shores of Lake Erie in Ashtabula, Ohio. Joe Latina participated in a study involving vitamin E pills. Vitamin E pills are linked with an increased risk for prostate cancer, according to follow-up data from a study aiming to see if the supplements could prevent the disease but halted when there were signs of possible harm. Men who had been randomly assigned to take vitamin E were 17 percent more likely to get prostate cancer than those given dummy pills, the follow-up report found. (AP Photo/Tony Dejak) In this Monday, Oct. 10, 2011 photo, Joe Latina, 71, is shown on his porch at his home in Ashtabula, Ohio. Latina participated in a study involving vitamin E pills. Vitamin E pills are linked with an increased risk for prostate cancer, according to follow-up data from a study aiming to see if the supplements could prevent the disease but halted when there were signs of possible harm. Men who had been randomly assigned to take vitamin E were 17 percent more likely to get prostate cancer than those given dummy pills, the follow-up report found. (AP Photo/Tony Dejak)eval("var currentItemd57851005a80479aaeeb90a12c70b9ff = 1;");eval("var nextd57851005a80479aaeeb90a12c70b9ff = 0;");eval("var previousd57851005a80479aaeeb90a12c70b9ff = 0;"); CHICAGO (AP) — There is more evidence that taking vitamin E pills can be risky. A study that followed up on men who took high doses of the vitamin for about five years found they had a slightly increased risk of prostate cancer — even after they quit taking the pills.

Doctors say it's another sign that people should be careful about using vitamins and other supplements.

"People tend to think of vitamins as innocuous substances, almost like chicken soup — take a little and it can't hurt," said lead author Dr. Eric Klein of the Cleveland Clinic. The study shows that is not true.

"If you have normal levels, the vitamin is probably of no benefit, and if you take too much, you can be harmed," Klein said.

Men randomly assigned to take a 400-unit capsule of vitamin E every day for about five years were 17 percent more likely to get prostate cancer than those given dummy pills. That dose, commonly found in over-the-counter supplements, is almost 20 times higher than the recommended adult amount, which is about 23 units daily.

The results mean for every 1,000 men who took vitamin E, there were 11 additional cases of prostate cancer, compared with men taking dummy pills.

The study was actually launched to try to confirm less rigorous research suggesting vitamin E might protect against prostate cancer. Overall, about 160 of every 1,000 U.S. men will develop prostate cancer in their lifetime.

Risks increase as men age. Detection can be tricky since symptoms such as frequent urination can also be caused by harmless conditions, and doctors disagree about the benefits of screening tests. Treatment is also complex since some slow-growing prostate cancers are not deadly but some procedures, including surgery, can damage sexual function and cause incontinence.

Just last week, a government-convened panel of experts recommended against routine PSA screening for prostate cancer. That draft advice is open for public comment.

What should vitamin E users do, given the new study results? About 13 percent of American men take it, according to a supplement trade group.

Dr. Otis Brawley, chief medical officer for the American Cancer Society, says they should stop taking large doses and talk to their doctors about risks and benefits from prostate cancer screening. Smaller doses, typically found in multivitamins, are probably fine, said Brawley, who was not involved in the research.

Vitamin E is found in foods such as nuts, seeds and vegetable oils. The nutrient helps nerves, muscles, blood vessels and the immune system function.

Vitamin E supplements have long been promoted for disease prevention, but scientific research has disproven many claims and suggested they might increase risks for some conditions, including heart failure.

Brawley noted that the study echoes previous thinking on beta-carotene, which once was thought to protect against cancer but more recently has been linked with increased risks for lung cancer, especially in smokers.

"There should be a global warning that ... excessive use of vitamins has not been proven to be beneficial and may be the opposite," Brawley said.

Experts generally agree that foods are the best sources for vitamins.

The new research appears in Wednesday's Journal of the American Medical Association. The National Cancer Institute and National Center for Complementary and Alternative Medicine paid for the multimillion-dollar study.

Joe Latina, a cabinet shop owner in Aurora, Ohio, was among study participants. He said researchers gave him pills they said "might slow down prostate cancer." Now 71 and cancer-free, he says he doesn't know whether he was given vitamins or dummy pills.

Latina said he "was kind of surprised" by the study results, but is not stressing out over the possibility that he still might get cancer.

"I'm a positive thinker," he said. "I'm not walking around saying, 'Oh my God, the other shoe is going to drop. I don't think I have any way to control it."

The study involved more than 35,000 healthy men aged 50 and older, from the United States, Canada and Puerto Rico. They were randomly assigned to take daily vitamin E or selenium supplements, both pills or dummy pills. The study was halted after about five years when there were signs of no benefit and a possible increased risk for prostate cancer in vitamin E users. The researchers continued tracking the men even after they stopped taking pills.

The follow-up found that a potential link between selenium and diabetes was a false alarm, but it confirmed signs of a vitamin E-prostate cancer link. Over a total of about seven years, there were 76 cases of prostate cancer diagnosed per 1,000 men, versus 65 cases in men given dummy pills.

"The implications of our observations are substantial," the study authors said.

The results suggest that extra risks associated with taking relatively high doses of vitamin E continue even after supplements are stopped. The researchers said it is unclear how vitamin E would harm the prostate.

There was no increased risk for men who took both vitamin E and selenium, suggesting that selenium might somehow counter the harmful effects of vitamin E, the study authors said.

Duffy MacKay of the Council for Responsible Nutrition, a supplement makers' trade group, said the study shouldn't be interpreted as questioning the benefits of vitamin E as an essential nutrient, and he said there is evidence that many Americans don't get enough.

___

Online:

JAMA: http://www.jama.ama-assn.org

National Cancer Institute: http://www.cancer.gov

PSA recommendations: http://www.ahrq.gov

__

AP Medical Writer Lindsey Tanner can be reached at http://www.twitter.com/LindseyTanner .

Associated Press

Technology



News

Senin, 10 Oktober 2011

New prostate cancer test advice overturns dogma

AppId is over the quota
AppId is over the quota
In this Sept. 13, 2011 photo provided by the University of Chicago Medical Center, Dr. Gautam Jayram assists during prostate cancer surgery, watching an internal video of the patient’s body, at the University of Chicago Medical Center in Chicago. No major medical group recommends routine PSA (prostate-specific antigen) blood tests to check men for prostate cancer, and now a government panel is saying they do more harm than good and healthy men should no longer receive the tests as part of routine cancer screening. The recommendation by the U.S. Preventive Services Task Force, being made public on Friday, Oct. 7, 2011 will not come as a surprise to cancer specialists. The task force concluded there's little if any mortality benefit. But there is harm from routine screening: impotence, incontinence, infections, even death that can come from the biopsies, surgery and radiation, according to Dr. Virginia Moyer of the Baylor College of Medicine, who heads the task force. (AP Photo/University of Chicago Medical Center, Bruce Powell) In this Sept. 13, 2011 photo provided by the University of Chicago Medical Center, Dr. Gautam Jayram assists during prostate cancer surgery, watching an internal video of the patient’s body, at the University of Chicago Medical Center in Chicago. No major medical group recommends routine PSA (prostate-specific antigen) blood tests to check men for prostate cancer, and now a government panel is saying they do more harm than good and healthy men should no longer receive the tests as part of routine cancer screening. The recommendation by the U.S. Preventive Services Task Force, being made public on Friday, Oct. 7, 2011 will not come as a surprise to cancer specialists. The task force concluded there's little if any mortality benefit. But there is harm from routine screening: impotence, incontinence, infections, even death that can come from the biopsies, surgery and radiation, according to Dr. Virginia Moyer of the Baylor College of Medicine, who heads the task force. (AP Photo/University of Chicago Medical Center, Bruce Powell)eval("var currentItemd57851005a80479aaeeb90a12c70b9ff = 1;");eval("var nextd57851005a80479aaeeb90a12c70b9ff = 0;");eval("var previousd57851005a80479aaeeb90a12c70b9ff = 0;"); WASHINGTON (AP) — Men finally may be getting a clearer message about undergoing PSA screening for prostate cancer: Don't do it.

They may not listen. After all, the vast majority of men over 50 already get tested.

The idea that finding cancer early can harm instead of help is a hard one to understand. But it's at the heart of a government panel's draft recommendation that those PSA blood tests should no longer be part of routine screening for healthy men.

The U.S. Preventive Services Task Force examined all the evidence and found little if any reduction in deaths from routine PSA screening. But it did conclude that too many men are diagnosed with tumors that never would have killed them and suffer serious side effects from resulting treatment.

That recommendation isn't final — it's a draft open for public comment. But it goes a step further than several major cancer groups including the American Cancer Society, which urges that men be told the pros and cons and decide for themselves.

The new advice is sure to be hugely controversial. Already some doctors are rejecting it.

"We all agree that we've got to do a better job of figuring out who would benefit from PSA screening. But a blanket statement of just doing away with it altogether ... seems over-aggressive and irresponsible," said Dr. Scott Eggener, a prostate cancer specialist at the University of Chicago.

In the exam room, explaining the flaws in PSA testing has long been difficult.

"Men have been confused about this for a very long time, not just men patients but men doctors," said Dr. Yul Ejnes, a Cranston, R.I., internal medicine specialist who chairs the American College of Physicians' board of regents.

He turned down his own physician's offer of a PSA test after personally reviewing the research.

"There's this dogma ... that early detection saves lives. It's not necessarily true for all cancers," Ejnes said.

That's an emotional shift, as the American Cancer Society's Dr. Len Lichtenfeld voiced on his blog on Friday.

"We have invested over 20 years of belief that PSA testing works. ... And here we are all of these years later, and we don't know for sure," Lichtenfeld wrote. "We have been poked and probed, we have been operated on by doctors and robots, we have been radiated with fancy machines, we have spent literally billions of dollars. And what do we have? A mess of false hope?"

Too much PSA, or prostate-specific antigen, in the blood only sometimes signals prostate cancer is brewing. It also can mean a benign enlarged prostate or an infection. In fact, most men who undergo a biopsy for an abnormal PSA test don't turn out to have prostate cancer.

Screening often detects small tumors that will prove too slow-growing to be deadly — by one estimate, in 2 of every 5 men whose cancer is caught through a PSA test. But there's no way to tell in advance who needs treatment.

"If we had a test that could distinguish between a cancer that was going to be aggressive and a cancer that was not, that would be fabulous," said Dr. Virginia Moyer of the Baylor College of Medicine, who chairs the task force, an independent expert group that reviews medical evidence for the government.

About 1 in 6 U.S. men will be diagnosed with prostate cancer at some point in their life. Yet the cancer society notes that in Western European countries where screening isn't common, 1 in 10 men are diagnosed and the risk of death in both places is the same. In the U.S., about 217,000 men are diagnosed with prostate cancer each year, and 32,000 die.

Why not screen in case there's a mortality benefit that studies have yet to tease out? The task force outlined the problem with that:

—Up to 5 in every 1,000 men die within a month of prostate cancer surgery, and between 10 and 70 more suffer serious complications.

—At least 200 to 300 of every 1,000 men treated with surgery or radiation suffer incontinence or impotence.

—Overall, Moyer said 30 percent of men who are treated for PSA-discovered prostate cancer suffer significant side effects from the resulting treatment.

Among the questions sure to be raised during the public comment period are how doctors should advise men with prostate cancer in the family or black men, who are at increased risk.

PSA testing also is used to examine men with prostate symptoms, and to check men who already have had prostate cancer. The new recommendation doesn't affect those uses.

Congress requires that Medicare cover PSA tests, at a cost of $41 million in 2009. Other insurers follow Medicare's lead, especially in light of conflicting recommendations.

Nor does the new recommendation mean that men who want a PSA test can't have one. If the rule is adopted — something the government will review once the task force hears comments and finalizes its guidance — it would just advise against doctors pushing it routinely.

"The truth is that like so many things in medicine, there's no one-size-fits-all," said Dr. Michael Barry of Massachusetts General Hospital who heads the Foundation for Informed Medical Decision-Making that backs ways to help patients make their own choices.

___

AP Medical Writer Lindsey Tanner in Chicago contributed to this report.

___

Online:

PSA decision guide: http://bit.ly/cXq1QE

Associated Press

Technology



News

Sabtu, 08 Oktober 2011

Panel expected to say no prostate screenings for men

AppId is over the quota
AppId is over the quota
Study: Men don't need prostate examsNEW: Prostate Cancer Foundation spokesman calls recommendation a mistakeNEW: But author of report says he believes testing does more harm than goodU.S. Preventive Services Task Force to give prostate specific antigen testing a "D" ratingIt says tests bring "small or no reduction" in prostate cancer deaths

(CNN) -- The U.S. Preventive Services Task Force, the group that told women in their 40s that they don't need mammograms, will soon recommend that men not get screened for prostate cancer, according to a source privy to the task force deliberations.

The task force is set to recommend a "D" rating for prostate specific antigen, or PSA, testing. Such a rating means "there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits," according to the group's website. The task force is set to propose this recommendation Tuesday, and then allow for a comment period before issuing a final recommendation.

According to a draft copy of a report released Friday, a review of studies shows screening with the PSA blood test results in "small or no reduction" in prostate cancer deaths.

The report adds that PSA testing is "associated with harms related to subsequent evaluation and treatments."

The PSA test, which is sometimes accompanied by a digital rectal exam, can help determine if a man has prostate cancer. The problem is that many of the cancers that get detected are so small and slow-growing, they'll never be harmful, and doctors have a difficult time discerning the quick, harmful cancers from the slow, harmless ones.

Empowered Patient: What's a dude to do?

If you test 100 men over age 50, 17 of them will have prostate cancer, and only three of those will have a fast-growing cancer and die of the disease, according to Dr. Kenneth Lin, senior author of the paper.

If the 14 men with the slow-growing cancers are treated, they could be rendered impotent or incontinent from the treatment; or worse, the treatment could kill them. About one in 500 men who has a radical prostatectomy will die because of complications of the surgery, according to Lin.

Some prostate cancer patients were disappointed with the task force's decision.

A spokesman for the Prostate Cancer Foundation called the proposed recommendation "a tremendous mistake."

"You're talking to someone whose life was saved by [the PSA test]," Dan Zenka said.

But Lin says he believes testing does more harm than good.

"Maybe you should get tested if you have this horrible family history where everyone gets prostate cancer before the age of 50. But for most men, testing is harmful," he said.

Until last year, Lin worked with the Preventive Services Task Force as a medical officer for the Agency for Healthcare Research and Quality. He says the task force voted in 2009 to give PSA screening a "D" rating, but it didn't announce it because of the uproar over the mammogram recommendation.

"I was so frustrated with the political interference, and this was the final straw," said Lin, who left the group in November and is now an assistant professor of family medicine at Georgetown University Medical Center.

CNN's Jennifer Bixler and Aaron Cooper contributed to this report.



Education Information



Technology

Panel Advises Against Routine Prostate Screening

AppId is over the quota
AppId is over the quota
Visuals Unlimited, Inc. / Dr. Gladden Willis / Getty Images Visuals Unlimited, Inc. / Dr. Gladden Willis / Getty Images

No major medical group recommends routine PSA blood tests to check men for prostate cancer, and now a government panel is saying they do more harm than good and healthy men should no longer receive the tests as part of routine cancer screening.

The panel's guidelines had long advised men over 75 to forgo the tests and the new recommendation extends that do-not-screen advice to healthy men of all ages.

The recommendation by the U.S. Preventive Services Task Force, being made public on Friday, will not come as a surprise to cancer specialists.

Yet, most men over 50 have had at least one PSA blood test, the assumption being that finding cancer early is always a good thing.

Not so, said Dr. Virginia Moyer of the Baylor College of Medicine, who heads the task force.

"We have put a huge amount of time, effort and energy into PSA screening and that time, effort and energy, that passion, should be going into finding a better test instead of using a test that doesn't work," Moyer told The Associated Press late Thursday.

Too much PSA, or prostate-specific antigen, in the blood only sometimes signals prostate cancer is brewing. It also can mean a benign enlarged prostate or an infection. Worse, screening often detects small tumors that will prove too slow-growing to be deadly. And there's no sure way to tell in advance who needs aggressive therapy.

MORE: Saw Palmetto No Better Than Placebo for Prostate Symptoms

The task force analyzed all the previous research on this subject, including five major studies, to evaluate whether routine screening reduces deaths from prostate cancer. The conclusion: There's little if any mortality benefit.

But there is harm from routine screening: impotence, incontinence, infections, even death that can come from the biopsies, surgery and radiation, Moyer said.

One study estimated 2 of every 5 men whose prostate cancer was caught through a PSA test had tumors too slow-growing to ever be a threat.

Yet Moyer said 30 percent of men who are treated for PSA-discovered prostate cancer suffer significant side effects, sometimes death, from the resulting treatment.

About a third of men ages 40 to 60 have brewing prostate cancer but "the huge majority of them will never know it in their lifetime if they are not screened," she added.

MORE: Screening for Ovarian Cancer Doesn't Increase Women's Survival

The task force previously had considered the evidence for or against PSA screening inconclusive. The new recommendation says not to routinely screen. That recommendation is a draft that is open for public comment beginning next week.

"We have been long concerned, and it has been apparent for some years, that some supporters of prostate cancer screening have overstated, exaggerated and in some cases misled men about the evidence supporting its effectiveness," said Dr. Otis Brawley of the American Cancer Society in a statement. "We need balanced, truthful information to be made widely available to physicians and patients when making important health decisions."

The society had not seen the new recommendation yet, but has long advised men to consider the pros and cons of PSA screening before deciding on their own.

Moyer said the recommendation only means that doctors shouldn't bring up the option for healthy men. If a man asks for a PSA test and wants it after being informed of the evidence, he should receive it, she said. Likewise, it's appropriate to use PSA tests to examine a man with possible prostate symptoms.

—By LAURAN NEERGAARD



News



Debt Financing

PSA test for prostate cancer not recommended: panel

AppId is over the quota
AppId is over the quota
By Julie Steenhuysen

CHICAGO | Fri Oct 7, 2011 1:43pm EDT

CHICAGO (Reuters) - A U.S. government-backed panel recommended against routine prostate cancer screening on Friday because widespread screening for the disease causes more harm than good.

The U.S. Preventive Services Task Force had previously said there was not enough evidence to make a call on the use of prostate-specific antigen, or PSA, tests that measure levels in the blood of a protein.

The same panel caused a media storm in 2009 after it recommended doctors scale back on routine mammograms for women in their 40s and 50s.

The panel, which advises the government on health prevention measures, downgraded its recommendation on prostate cancer screening to a "D," which means it recommends against the service because "there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits."

The proposed guidelines are meant to discourage use of the test for healthy men who do not have any symptoms that might indicate prostate cancer. They do not apply to the use of PSA tests as part of a diagnostic strategy in men suspected of having prostate cancer.

High or increasing levels of PSA can indicate an increased risk for prostate cancer, but elevated PSA levels can be caused by other things too, such as infections, an enlarged prostate or even recent ejaculation.

Studies have shown that widespread use of PSA tests has resulted in high rates of false positives and overtreatment for an often slow-growing cancer that might never have caused harm.

And the treatments -- usually surgery and radiation -- are not benign. They frequently result in impotence and incontinence.

Simply being diagnosed with prostate cancer can cause anxiety and harm. A study by researchers at Harvard and Brigham & Women's Hospital in Boston last year found that being diagnosed with prostate cancer roughly doubles the risk of suicide or death from a heart attack.

MIXED RESULT ON PSA TEST EFFECTIVENESS

But prostate cancer is not harmless. It is the second-leading cause of cancer death in the United States behind lung cancer.

"The notion that prostate cancer is not a threat to the well being of men is simply wrong," said Dr. Herbert Lepor, a urology professor at New York University School of Medicine.

Results of studies looking at the benefits of widespread prostate cancer screening have been mixed, according to the conclusions of a review of studies set to be published next week but released early by the Annals of Internal Medicine.

That review, which is used by the task force to make its recommendations, noted that of the five screening trials it studied, the two largest and highest-quality studies reported conflicting results. One found screening was associated with reduced prostate cancer deaths compared with no screening in men age 55 to 69 after nine years.

The other found no statistically significant benefit after 10 years. And of the men who had three or four rounds of screening, the false positive rate was 12 to 13 percent.

"Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary," the report concluded.

But critics say the studies were not long enough to show a benefit and argued that there is evidence that PSA screening saves lives.

"The U.S. Preventive Services Task Force claims the screening studies fail to show benefits of screening. This is not accurate," Lepor said.

A Scandinavian study with 14 years of follow up showed prostate cancer screening cut prostate cancer deaths by 50 percent, Lepor said.

"The U.S. Preventive Services Task Force is a group of primary care physicians like pediatricians and OB/GYNs who never treat prostate cancer. They have simply misinterpreted the studies and have not seen men die of this fatal disease," Lepor said.

The guidelines had been scheduled to be released in the Annals of Internal Medicine on Monday, but leaks of the recommendations to news outlets forced the group to post the guidelines early. It was first reported by CNN on Thursday.

The recommendations will be available for a 30-day comment period before final treatment guidelines are released.

According to the American Cancer Society, about 1 man in 6 will be diagnosed with prostate cancer during his lifetime. More than 2 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

(Editing by Jackie Frank)



New Automobile



Health Management

Jumat, 07 Oktober 2011

FDA OKs Eli Lilly's Cialis for enlarged prostate

AppId is over the quota
AppId is over the quota

n">(Reuters) - U.S. drug regulators approved Eli Lilly's Cialis drug to treat enlargement of the prostate on Thursday, expanding use of the blockbuster impotence medicine.

The Food and Drug Administration said Cialis could be labeled for treatment of the signs and symptoms of a non-cancerous enlarged prostate, called benign prostatic hyperplasia (BPH), and also be used for people who have both BPH and erectile dysfunction.

About half of men over 50 suffer from prostate problems, which can cause difficulty urinating.

"BPH can have a big impact on a patient's quality of life," said Scott Monroe, director of the FDA's division of reproductive and urologic products. "Cialis offers these men another treatment option, particularly those who also have ED (erectile dysfunction), which is also common in older men."

U.S. researchers reported in the journal Urology in 2008 that impotence drugs could help reduce the symptoms caused by an enlarged prostate.

The FDA said it has approved eight other drugs to treat BPH, including Merck & Co's Proscar, GlaxoSmithKline's Avodart and Pfizer's Cardura.

In an interview in July, Eli Lilly CEO John Lechleiter said he expects the longer-lasting Cialis to overtake Pfizer's Viagra to become the market leader for impotence drugs.

Cialis, which the FDA approved for impotence in 2003, posted sales of $1.7 billion in 2010, up nine percent from the previous year, while global Viagra sales climbed two percent last year to $1.9 billion.



New Automobile



Health Management

Prostate Cancer Screening: What You Need to Know

AppId is over the quota
AppId is over the quota

A panel of cancer experts is recommending against testing for prostate-specific antigen (PSA), the most commonly used prostate cancer screen, in healthy men.

According to its review of the best available data, the U.S. Preventive Services Task Force (USPSTF) concludes that the potential harms of PSA testing — which include further, more invasive testing that may result in impotence and incontinence — outweigh any benefits in healthy men. The panel is expected to release on Tuesday a comprehensive report detailing the value of PSA testing, but the group's draft recommendation was made public this week.

What does this mean for men who are concerned about prostate cancer? Here's some information that can help you decide whether it's right for you.

What is the PSA test?

The PSA test is a blood test that measures levels of prostate-specific antigen, a protein produced by cells of the prostate gland. It tends to show up on cancer cells, so higher levels of the antigen could be a sign of tumors. Men normally have low levels of PSA, but those levels may rise for reasons unrelated to cancer, which is why a high PSA level alone cannot be used to determine whether a man has cancer or some other benign condition.

What conditions other than prostate cancer can raise PSA levels?

There are many: benign growth of the prostate (the gland typically enlarges with age), infection or inflammation of the prostate, ejaculation, and riding a bicycle can all push PSA levels higher.

Who should get the PSA test?

Currently, there is no major medical group that recommends routine PSA testing, but millions of men over age 50 get it. The American Cancer Society, for example, does not have a specific recommendation for routine screening of healthy men without symptoms of prostate cancer, but it advises otherwise healthy men who have reason for concern about increased prostate risk to begin discussing screening with their doctors at age 50. That's because the risk of prostate cancer tends to increase with age.

MORE: Saw Palmetto No Better Than Placebo for Prostate Symptoms



News



Debt Financing

Selasa, 27 September 2011

Roche bone drug eases pain in prostate cancer trial

AppId is over the quota
AppId is over the quota
A worker makes its way on a bridge at Swiss pharmaceutical company Roche plant in Basel February 2, 2011. REUTERS/Christian Hartmann

A worker makes its way on a bridge at Swiss pharmaceutical company Roche plant in Basel February 2, 2011.

Credit: Reuters/Christian Hartmann

By Kate Kelland

STOCKHOLM | Sun Sep 25, 2011 6:29am EDT

STOCKHOLM (Reuters) - Roche's bone strengthening drug Boniva is as good for pain relief as single dose radiotherapy in patients whose prostate cancer has spread to their bones, according to data from a late-stage trial released on Sunday.

Trial investigators said the level side effects of Boniva -- known generically as ibandronate (IB) -- were also comparable with radiotherapy, suggesting it could offer an alternative option for advanced cancer patients suffering pain.

Bone metastases, or secondary tumors in the bone, are common in many advanced cancers and "are a serious problem for men with prostate cancer," said Peter Hoskin a professor clinical oncology at University College, London, who presented the data at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm on Sunday.

"We found that using IB was as good as single dose radiotherapy in controlling pain," he said.

Boniva is one of a class of osteoporosis drugs known as bisphosphonates, which work by sticking to calcium and binding to it. Others in the same class include Novartis's Zometa and Merck's Fosamax.

They prevent bone loss by inhibiting the activity of cells that break down bone, called osteoclasts.

For the late stage, or Phase III, trial, researchers gave 470 patients with painful secondary tumors in the bone either a single dose of radiation or an intravenous infusion of Boniva.

Patients reported their main site of pain when they began the trial, and then again at four, eight, 12, 26 and 52 weeks after treatment.

Those who had not responded to the first treatment at four weeks crossed over to the alternative therapy and received their second treatment no later than week eight.

Pain levels were measured at four and 12 weeks by analysing how many painkillers patients were needing to take, and by scoring their reported pain levels using two standard methods called the WHO pain ladder and the Mercadante method.

"Although there were more patients in the IB group with worse Mercadante scores at four weeks who needed re-treatment, at six and 12 months, there was no long-term difference in pain relief between the two groups," Hoskin said

The median survival of the four groups was 11.8 months for those on radiotherapy only, 11.4 months for those on the Roche drug only, 12.7 months for those on radiotherapy then Boniva, and 16.8 months for those on Boniva and then radiotherapy.

But Hoskin said it was too early to draw any conclusions from these data about the drug's relative impact on survival in this group of patients.

"We hope to analyze these survival differences further in the hope that it can give us... pointers as to how and whether we should use a combination of treatments," he said. "Currently we are unsure about the optimal timing and scheduling of treatment for these patients."

For now Hoskin said Boniva, which is also sold under the brand name Bonviva, would be addition to the arsenal of other possible treatments for cancer pain and could potentially be useful in other types of the diseases such as breast cancer, where secondary bone tumors are also common.

(Editing by John Stonestreet)



View the original article here



Peliculas Online

Sabtu, 24 September 2011

Bayer drug a "major new player" in prostate cancer

AppId is over the quota
AppId is over the quota
By Kate Kelland

STOCKHOLM | Fri Sep 23, 2011 6:12pm EDT

STOCKHOLM (Reuters) - An experimental drug from Germany's Bayer and Norwegian biotech Algeta that prolongs the lives of patients with advanced prostate cancer is a major step forward in treatment of the disease, cancer experts said on Saturday.

A late stage trial of Alpharadin, a new type of drug that delivers minute, highly-charged doses of radiation to secondary tumors in the bone, was halted early after researchers saw patients on the new treatment living almost three months longer on average than those on standard treatment plus placebo.

"It would have been unethical not to offer the active treatment to those taking placebo," Chris Parker, who led the trial at Britain's Royal Marsden Hospital, told delegates at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm.

Alpharadin is based on the active ingredient radium 223 and is designed to treat patients with advanced disease whose cancer has spread to their bones.

Parker said he expected the drug to become a new standard treatment for these patients. Both Jean Charles Soria, a co-chair of the EMCC congress, and Michael Baumann, president of the European Cancer Organization, said Alpharadin was "a major new player" and likely to be "practice changing."

Kemal Malik, Bayer's head of global development, has described the success of Alpharadin -- which first showed promise in headline data released in June -- as a "transforming moment" for the company.

Sales of Alpharadin are expected to reach $662 million by 2015, according to consensus forecasts from Thomson Reuters Pharma. The drug's performance is also particularly important for Algeta, whose fortunes are tied closely its success.

Parker said the two firms now intend to use the data to submit the drug for regulatory approval.

TARGETED

Alpharadin is from a class of drugs called alpha-pharmaceuticals which work by sending tiny, charged, targeted doses of damaging radiation to a secondary tumour -- known as a metastasis -- in the bone.

Because it is so targeted, side effects are minimal in comparison with more conventional treatments, a factor that is likely to boost its popularity with patients and doctors.

"Compared to chemotherapy, which affects all the tissues of the body, radium-223 is highly targeted to the bone metastases, and it has a completely different safety profile," Parker explained. In the trial, he said, the drug was "extremely well tolerated."

Radium is similar to calcium in that it sticks to bone, particularly to where new bone is being formed, so it is a highly effective way of delivering radiation to a target.

"It takes only a single alpha particle to kill a cell," Parker said. "And collateral damage is minimised because the particles have such a tiny range -- a few millionths of a meter -- so we can be sure that the damage is being done where it should be, to the metastasis."

Parker's team studied the drug in patients with prostate cancer because it has a high tendency to spread to the bones. Around 90 percent of all men with prostate cancer will develop bone metastases in the advanced stages of the disease.

Prostate cancer is also the second most common cancer in men after lung cancer, killing an estimated 255,000 men each year.

Complete data from the trial showed that the median overall survival period for patients on the new drug was 14 months compared with 11.2 months for the placebo. The hazard ratio was 0.695, meaning that patients taking Alpharadin had a 30 percent lower rate of death compared to patients taking placebo.

(Reporting by Kate Kelland)



View the original article here



Peliculas Online

Senin, 19 September 2011

Bobby Bowden reveals he had prostate cancer

AppId is over the quota
AppId is over the quota
Bobby Bowden said he learned he had cancer after a routine examination by the Florida State team doctor.Bobby Bowden says he was treated for cancer while coachingHe did not want to reveal the disease for fear of giving competitors an edgeThe retired Florida State coach is now cancer freeBowden urges men to talk with their doctors about prostate cancer screenings

(CNN) -- Retired Florida State football coach Bobby Bowden revealed Tuesday that he was secretly treated for prostate cancer in 2007 while he was still coaching.

"I wasn't ashamed of it," Bowden said in an appearance on CNN explaining why he did not reveal the disease sooner. "I didn't want it to get out because I didn't want my opponents to use it against me."

He said other coaches would have used the information to steal recruits from the Florida State program that he led to two national championships, 12 conference championships and 28 consecutive bowl games on the way to amassing more than 300 wins. Bowden retired in 2009.

Bowden said he learned he had cancer after a routine examination by the Florida State team doctor, Kris Stowers. A few days after the exam, Stowers called and said a blood test had revealed a "little problem," said Bowden, who was 77 when he was diagnosed.

Stowers quickly arranged a clandestine visit to a urologist Bowden once coached.

"Then he said, 'Bring your wife,'" Bowden said. "That scared me."

In a USA Today interview, the doctor, Joe Camps, said he treated Bowden under an assumed identity in a midnight operation at a Florida hospital.

"But I am absolutely stunned this has remained secret for so long," the newspaper quoted Camps as saying.

Bowden had small radioactive pellets surgically implanted in his prostate to kill the cancer cells and is now cancer free, according to the USA Today story.

Bowden made the revelation during Prostate Cancer Awareness Month as part of his affiliation with On the Line, a prostate cancer awareness program.

He urged men to talk with their doctors about being tested for the disease.

About one in every six men will be diagnosed with prostate cancer, according to the American Cancer Society.



View the original article here



Peliculas Online

Jumat, 16 September 2011

HEALTH MANAGEMENT. Bobby Bowden reveals he had prostate cancer

Bobby Bowden said he learned he had cancer after a routine examination by the Florida State team doctor.Bobby Bowden says he was treated for cancer while coachingHe did not want to reveal the disease for fear of giving competitors an edgeThe retired Florida State coach is now cancer freeBowden urges men to talk with their doctors about prostate cancer screenings
(CNN) -- Retired Florida State football coach Bobby Bowden revealed Tuesday that he was secretly treated for prostate cancer in 2007 while he was still coaching.
"I wasn't ashamed of it," Bowden said in an appearance on CNN explaining why he did not reveal the disease sooner. "I didn't want it to get out because I didn't want my opponents to use it against me."
He said other coaches would have used the information to steal recruits from the Florida State program that he led to two national championships, 12 conference championships and 28 consecutive bowl games on the way to amassing more than 300 wins. Bowden retired in 2009.
Bowden said he learned he had cancer after a routine examination by the Florida State team doctor, Kris Stowers. A few days after the exam, Stowers called and said a blood test had revealed a "little problem," said Bowden, who was 77 when he was diagnosed.
Stowers quickly arranged a clandestine visit to a urologist Bowden once coached.
"Then he said, 'Bring your wife,'" Bowden said. "That scared me."
In a USA Today interview, the doctor, Joe Camps, said he treated Bowden under an assumed identity in a midnight operation at a Florida hospital.
"But I am absolutely stunned this has remained secret for so long," the newspaper quoted Camps as saying.
Bowden had small radioactive pellets surgically implanted in his prostate to kill the cancer cells and is now cancer free, according to the USA Today story.
Bowden made the revelation during Prostate Cancer Awareness Month as part of his affiliation with On the Line, a prostate cancer awareness program.
He urged men to talk with their doctors about being tested for the disease.
About one in every six men will be diagnosed with prostate cancer, according to the American Cancer Society.